Table 1

Distribution of patients’ clinicopathological characteristics according to treatment received

All patients
N (%)		Platinum-based
N (%)		PLD/trabectedin
N (%)		P value
All cases522626
Median age at diagnosis (range), years58 (35–79)59 (38–79)56 (35–73)0.14
Type of BRCA mutation
 wtBRCA
 mutBRCA		23 (44.3)
29 (55.7)		11 (42%)
15 (58%)		12 (46.2%)
14 (53.8%)		0.78
Histotype
 HGSOC
 Others		49 (94.2%)
3 (5.8%)		26 (100%)
0		23 (88.5%)
3 (11.5%)		0.07
Grading
 G1
 G2
 G3		0
0
52		0
0
26 (100%)		0
0
26 (100%)
FIGO stage at diagnosis
 III
 IV		45 (86.5%)
7 (13.5%)		22 (84.6%)
4 (15.4%)		23 (88.5%)
3 (11.5%)		0.15
Platinum-free interval*
 6–12 months
 >12 months		27 (52)
25 (48)		3 (11.5)
23 (88.5)		24 (92.3)
2 (7.7)		<0.001
Prior regimens
 1
 2
 3
 4
 ≥5		0
2 (3.8%)
41 (78.8%)
8 (15.5%)
1 (1.9%)		0
1 (3.8%)
20 (76.9%)
4 (15.5%)
1 (3.8%)		0
1 (3.8%)
21 (80.7%)
4 (15.5%)
0		0.79
Type of PARPi
 Olaparib
 Niraparib
 Rucaparib		20 (38.5%)
30 (57.7%)
2 (3.8%)		11 (42.3%)
15 (57.7%)
0		9 (34.6%)
15 (57.7%)
2 (7.7%)		0.33

  • *Estimated from last platinum treatment received.

  • .FIGO, International Federation of Gynecology and Obstetrics; HGSOC, high grade serous ovarian cancer; PARPi, poly (ADP-ribose) polymerase inhibitor; PLD, pegylated liposomal doxorubicin.;